With the first section of its rolling new drug application (NDA) for fidaxomicin submitted to the FDA this week, Optimer Pharmaceuticals Inc. is seeking to be the first company on the U.S. market in 25 years with a new effective oral antibiotic to treat and prevent recurrences of Clostridium difficile infection (CDI), a disease that can cause serious diarrhea and other intestinal conditions, such as colitis, which sometimes results in death. (BioWorld Today) Read More
